- Home
- CYH vs STRO Comparison
CYH vs STRO Comparison
Compare CYH & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYH | STRO |
|---|---|---|
| Founded | 1985 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.7M | 332.8M |
| IPO Year | 2000 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CYH | STRO |
|---|---|---|
| Price | $2.89 | $16.03 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $3.28 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 926.6K | 296.1K |
| Earning Date | 04-21-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 196.67 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $12,485,000,000.00 | $38,419,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.17 | N/A |
| P/E Ratio | $32.67 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.41 | $0.72 |
| 52 Week High | $4.43 | $43.85 |
Technical Indicators
Market Signals| Indicator | CYH | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 47.82 | 30.44 |
| Support Level | $2.73 | $14.81 |
| Resistance Level | $3.00 | $17.33 |
| Average True Range (ATR) | 0.12 | 1.05 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 43.33 | 22.32 |
Price Performance
Historical ComparisonAbout CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.